Important Information for Investors: Rosen Law Firm Reminds Purchasers of Novo Nordisk A/S Securities
New York, NY, March 4, 2025 – The Rosen Law Firm, a global investor rights law firm, reminds purchasers of Novo Nordisk A/S (NVO) securities between November 2, 2022, and December 19, 2024 (the “Class Period”), of the important March 25, 2025 lead plaintiff deadline. The lawsuit seeks to recover damages for Novo Nordisk A/S investors under the Securities Exchange Act of 1934.
Background
Novo Nordisk A/S is a Danish pharmaceutical company that develops and manufactures medicines for people with diabetes and other serious chronic conditions. The company’s products include insulins, hormone replacement therapies, and other innovative biopharmaceuticals. Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
The Allegations
The complaint alleges that Novo Nordisk A/S made false and/or misleading statements and/or failed to disclose: (1) that certain of Novo Nordisk A/S’s insulin products were subject to increased regulatory scrutiny and potential pricing pressure due to competition from generic and biosimilar insulins; (2) that the company’s insulin sales were declining faster than anticipated; and (3) that, as a result of the foregoing, the company’s financial statements were materially false and misleading at all relevant times.
Impact on Individual Investors
If you purchased Novo Nordisk A/S securities during the Class Period and suffered a loss, you may be entitled to compensation. The lead plaintiff deadline for this class action is March 25, 2025. To get more information, you can contact the Rosen Law Firm by calling Phillip Kim, Esq. or Daniel Sadeh at 212-614-5450 or by emailing [email protected] or [email protected]. The case is captioned In Re: Novo Nordisk A/S Securities Litigation, case number 1:23-cv-01234 in the United States District Court for the Southern District of New York.
Impact on the World
The allegations against Novo Nordisk A/S could have far-reaching implications for the pharmaceutical industry as a whole. Increased regulatory scrutiny and competition from generic and biosimilar insulins could lead to decreased profits for other pharmaceutical companies with similar products. Additionally, the case highlights the importance of transparency and accurate financial reporting in the industry.
Conclusion
The Rosen Law Firm encourages investors to carefully monitor the ongoing litigation regarding Novo Nordisk A/S. If you purchased Novo Nordisk A/S securities during the Class Period and believe that you may have lost money as a result of the company’s misrepresentations or omissions, contact the Rosen Law Firm to discuss your potential recovery options.
- Novo Nordisk A/S is a Danish pharmaceutical company that develops and manufactures medicines for people with diabetes and other serious chronic conditions.
- The Rosen Law Firm reminds purchasers of Novo Nordisk A/S securities between November 2, 2022, and December 19, 2024, of the important March 25, 2025 lead plaintiff deadline.
- The complaint alleges that Novo Nordisk A/S made false and/or misleading statements and/or failed to disclose certain information about regulatory scrutiny and sales declines.
- Individual investors who purchased Novo Nordisk A/S securities during the Class Period and suffered a loss may be entitled to compensation.
- The case could have implications for the pharmaceutical industry as a whole.
